Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR/EMT pathway and stimulates p53 for TKI sensitization in NSCLC

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip et al. · Nature Medicine · 2015 · 1.5K citations · Full text

Egfr T790m, Oncology, Medicine +9

The coordinate regulation of the p53 and mTOR pathways in cells

Zhaohui Feng, Haiyan Zhang, Arnold J. Levine · Proceedings of the National Academy of Sciences · 2005 · 1.2K citations · Full text

Mitophagy, Molecular Biology, Cell Death +21

Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer

Zhenfeng Zhang, Jae Cheol Lee, Luping Lin et al. · Nature Genetics · 2012 · 1.2K citations · Full text

Oncology, Axl Kinase, Egfr-targeted Therapy +8

An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance

Lauren A. Byers, Lixia Diao, Jing Wang et al. · Clinical Cancer Research · 2012 · 1.1K citations · Full text

Regulation of eIF-4E BP1 Phosphorylation by mTOR

Kenta Hara, Kazuyoshi Yonezawa, Mark T. Kozlowski et al. · Journal of Biological Chemistry · 1997 · 514 citations · Full text